Lars Henning Engelholm
Overview
Explore the profile of Lars Henning Engelholm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
121
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Egstrand S, Mace M, Morevati M, Engelholm L, Thomsen J, Bruel A, et al.
PLoS One
. 2025 Jan;
20(1):e0316675.
PMID: 39761264
Secondary hyperparathyroidism (sHPT) is a significant clinical complication of CKD leading to bone abnormalities and cardiovascular disease. Current treatment based on activating the parathyroid calcium-sensing receptor (CaSR) using calcimimetics such...
2.
Egstrand S, Mace M, Morevati M, Nordholm A, Engelholm L, Thomsen J, et al.
Kidney Int
. 2022 Mar;
101(6):1232-1250.
PMID: 35276205
The molecular circadian clock is an evolutionary adaptation to anticipate recurring changes in the environment and to coordinate variations in activity, metabolism and hormone secretion. Parathyroid hyperplasia in uremia is...
3.
Fjaestad K, Romer A, Goitea V, Johansen A, Thorseth M, Carretta M, et al.
Oncogene
. 2022 Jan;
41(9):1364-1375.
PMID: 35017664
The development of immune checkpoint inhibitors (ICI) marks an important breakthrough of cancer therapies in the past years. However, only a limited fraction of patients benefit from such treatments, prompting...
4.
Norregaard K, Jurgensen H, Gardsvoll H, Engelholm L, Behrendt N, Soe K
Int J Mol Sci
. 2021 Jul;
22(13).
PMID: 34202300
Cancer-induced bone degradation is part of the pathological process associated with both primary bone cancers, such as osteosarcoma, and bone metastases originating from, e.g., breast, prostate, and colon carcinomas. Typically,...
5.
Nielsen C, van Putten S, Lund I, Melander M, Norregaard K, Jurgensen H, et al.
Oncotarget
. 2017 Jun;
8(27):44605-44624.
PMID: 28574834
A key task in developing the field of personalized cancer therapy is the identification of novel molecular targets that enable treatment of cancers not susceptible to other means of specific...
6.
Kriegbaum M, Jacobsen B, Fuchtbauer A, Hansen G, Christensen I, Rundsten C, et al.
Sci Rep
. 2016 May;
6:25833.
PMID: 27169360
C4.4A is a modular glycolipid-anchored Ly6/uPAR/α-neurotoxin multidomain protein that exhibits a prominent membrane-associated expression in stratified squamous epithelia. C4.4A is also expressed in various solid cancer lesions, where high expression...
7.
Nielsen C, Kjems J, Sorensen K, Engelholm L, Behrendt N
Expert Opin Drug Deliv
. 2014 Mar;
11(5):791-822.
PMID: 24669756
Introduction: Development of drugs based on RNA interference by small interfering RNA (siRNA) has been progressing slowly due to a number of challenges associated with the in vivo behavior of...
8.
Rono B, Engelholm L, Lund L, Hald A
PLoS One
. 2013 Mar;
8(3):e59942.
PMID: 23527289
The fibrinolytic activity of plasmin plays a fundamental role in resolution of blood clots and clearance of extravascular deposited fibrin in damaged tissues. These vital functions of plasmin are exploited...
9.
Hald A, Eickhardt H, Maerkedahl R, Feldborg C, Egerod K, Engelholm L, et al.
FASEB J
. 2012 Jul;
26(11):4445-57.
PMID: 22815383
Rearrangement of the skin during wound healing depends on plasmin and plasminogen, which serve to degrade fibrin depositions in the provisional matrix and thereby facilitate keratinocyte migration. In the current...